• 2032: hVIVO Interview - CEO Mo Khan on New RSV Human Challenge Trial & Company Growth

  • Feb 3 2025
  • Length: 9 mins
  • Podcast

2032: hVIVO Interview - CEO Mo Khan on New RSV Human Challenge Trial & Company Growth

Listen for free

View show details

  • Summary

  • In this exclusive interview, hVIVO CEO Mo Khan discusses the company’s latest human challenge trial contract with Inhalon Biopharma, testing a next-generation mucosal RSV antiviral. Mo addresses industry speculation around RSV trials, explains why RSV antivirals remain a key growth area, and shares insights on hVIVO’s strong sales pipeline conversion, with this being their fourth new study announcement in under two months. He also provides a quick update on the recent CRS acquisition and what’s next for the company.
    Show more Show less
Show more Show less

What listeners say about 2032: hVIVO Interview - CEO Mo Khan on New RSV Human Challenge Trial & Company Growth

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.ca reviews

Amazon Reviews
No reviews are available